Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial
Articolo
Data di Pubblicazione:
2007
Citazione:
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial / M.A. Konstam, M. Gheorghiade, J.C. Burnett, L. Grinfeld, A.P. Maggioni, K. Swedberg, J. E. Udelson, F. Zannad, T. Cook, J. Ouyang, C. Zimmer, C. Orlandi, P. Agostoni. - In: JAMA. - ISSN 0098-7484. - 297:12(2007 Mar 28), pp. 1319-1331.
Abstract:
Vasopressin mediates fluid retention in heart failure. Tolvaptan, a vasopressin V2 receptor blocker, shows promise for management of heart failure.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Administration, Oral ; Heart Failure ; Double-Blind Method ; Benzazepines ; Humans ; Receptors, Vasopressin ; Quality of Life ; Aged ; Blood Urea Nitrogen ; Cardiovascular Agents ; Sodium ; Body Weight ; Kaplan-Meier Estimate ; Creatinine ; Hospitalization ; Middle Aged ; Male ; Female
Elenco autori:
M.A. Konstam, M. Gheorghiade, J.C. Burnett, L. Grinfeld, A.P. Maggioni, K. Swedberg, J. E. Udelson, F. Zannad, T. Cook, J. Ouyang, C. Zimmer, C. Orlandi, P. Agostoni
Link alla scheda completa: